Kaleido key facts
- Developer of medical devices designed to be used for the treatment of diabetes.
- It has raised $193.6M; the latest was Later Stage VC ($98.0M) in Jan 2026.
- Notable investors include Invest-NL (Investment Company), EQT Life Sciences, ROM Utrecht Region, EQT, Partners in Equity — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Kaleido: the Monday email on marks, rounds and moves
Kaleido funding rounds
No funding rounds for Kaleido are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kaleido investors
10 investors are on record for Kaleido, including Invest-NL (Investment Company), EQT Life Sciences, ROM Utrecht Region and EQT.
About Kaleido
Developer of medical devices designed to be used for the treatment of diabetes. The company's device comes with multiple insulin pumps and a rechargeable and wireless handset wherein the pump system is integrated with the Diabeloop system to offer automated insulin delivery, enabling users to control their glucose level by choosing a conventional or patch pump style as per their blood group and live on their terms.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2013
- Employees
- 181
- Website
- hellokaleido.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kaleido doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.